RxDoctor Payments Data

Miranda Edgar, APRN

Family · Hot Springs, ARNPI 1013568997

Payments from drug & device makers

$5,132in general payments, 2019–2025

Across 332 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$464
  • Otsuka America Pharmaceutical, Inc.$419
  • AstraZeneca$369
  • Antares Pharma, Inc.$276
  • Pfizer$252
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$5,132100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,132 in reported general payments places this provider in the 90th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$54,835
Medicare patients
226
Services billed
3,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$30,316
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$29,962
RexultiBrexpiprazole15$28,230
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$18,649
LinzessLinaclotide25$17,639
EliquisApixaban17$16,566
FarxigaDapagliflozin Propanediol16$16,533
MounjaroTirzepatide15$16,231
GemtesaVibegron14$8,677
Pregabalin33$1,131
Albuterol Sulfate HfaAlbuterol Sulfate34$866
Testosterone Cypionate14$803
Clonazepam76$727
Omeprazole30$665
Rosuvastatin Calcium65$449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Farxiga$369$35,18135 claims
Novo NordiskOzempic$69$30,31626 claims
GSKTrelegy Ellipta$149$29,96239 claims
Otsuka America Pharmaceutical, Inc.Rexulti$419$28,23015 claims
AbbVieLinzess$1,548$17,63925 claims
PfizerEliquis$252$16,56617 claims
Lilly USA, LLCMounjaro$78$16,23115 claims
Almatica Pharma LLCSertraline Hcl$36$18622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,103 family providers in Arkansas.

Other family in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →